<DOC>
	<DOCNO>NCT01996865</DOCNO>
	<brief_summary>Follicular lymphoma ( FL ) , marginal zone lymphoma ( MZL ) , mantle cell lymphoma ( MCL ) distinct histologic type B-cell NHL . Lenalidomide immunomodulatory agent direct immune-mediated mechanism action , well clinical activity NHL . Recent study frontline relapsed/refractory NHL show high activity lenalidomide plus rituximab ( R2 ) , support study combination .</brief_summary>
	<brief_title>Lenalidomide Plus Rituximab Followed Lenalidomide Versus Rituximab Maintenance Relapsed/Refractory Follicular , Marginal Zone Mantle Cell Lymphoma .</brief_title>
	<detailed_description>MAGNIFY ( NCT01996865 ) phase 3b , multicenter , open-label study patient grade 1-3b transformed follicular lymphoma ( FL ) , marginal zone lymphoma ( MZL ) , mantle cell lymphoma ( MCL ) receive ≥1 prior therapy stage I-IV , measurable disease . ~500 patient plan enrollment 12 cycle R2 induction , project ~314 patient ≥SD induction randomize ( 1:1 ) two maintenance arm . Induction include oral lenalidomide 20 mg/day , day 1-21 per 28-day cycle ( d1-21/28 ) plus IV rituximab 375 mg/m2 , day 1 , 8 , 15 , 22 cycle 1 day 1 cycle 3 , 5 , 7 , 9 , 11 ( 28-day cycle ) . Patients randomized maintenance lenalidomide 10 mg/day , d1-21/28 , cycle 13-30 , plus rituximab 375 mg/m2 , day 1 cycle 13 , 15 , 17 , 19 , 21 , 23 , 25 , 27 , 29 ( R2 , Arm A ) , rituximab alone ( schedule , Arm B ) . Patients receive R2 maintenance 18 cycle may continue maintenance lenalidomide monotherapy 10 mg/day , d1-21/28 ( per patient and/or investigator discretion ) , disease progression tolerate . The primary endpoint progression-free survival ( per modify 1999 IWG criterion ) . Secondary endpoint include safety , overall survival , response rate , duration response , quality life ( exploratory ) . Patients follow ≥5 year last patient initiate induction therapy . Enrollment MAGNIFY begin March 2014 ; Jan 2016 , 133 patient enrol .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Age ≥18 year Histologically confirm Follicular Lymphoma ( Grade 1 , 2 3a ) , Marginal Zone Lymphoma , Mantle Cell Lymphoma Must document relapse , refractory Progressive Disease last treatment systemic therapy Bidimensionally measurable disease Eastern Cooperative Oncology Group ( ECOG ) Performance status ≤ 2 Adequate bone marrow function Willingness follow pregnancy precaution Histology follicular marginal zone lymphoma clinical evidence transformation Grade 3b follicular lymphoma Any medical condition ( underlying lymphoma ) require chronic steroid use Subjects take corticosteroid last 1 week prior treatment , unless administer dose equivalent &lt; 20 mg/day prednisone Systemic antilymphoma therapy within 28 day use antibody agent within 8 week use radioimmunotherapy within 3 month Known seropositive active viral infection hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) Known sensitivity allergy murine product Presence history central nervous system involvement lymphoma . Subjects risk thromboembolic event willing take prophylaxis . Any condition place subject unacceptable risk he/she participate study confounds ability interpret data study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lymphoma , Mantle cell Lymphoma , Follicular Lymphoma , Marginal zone Lymphoma , Lenalidomide treatment , rituximab treatment , Non Hodgkins Lymphoma</keyword>
</DOC>